174 related articles for article (PubMed ID: 35174404)
1. Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
Wang Y; Hou W; Li H; Tian X; Li J; Hu T; Shi D; Zhang Y
Ann Hematol; 2022 May; 101(5):1039-1047. PubMed ID: 35174404
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Zhang Y; Hou W; Cao F; Lu M; Yang H; Tian X; Wang Y; Hou J; Fu J; Li H; Zhou J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):485-492. PubMed ID: 31686248
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
4. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
5. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Hou J; Wang S; Zhang Y; Fan D; Li H; Yang Y; Ge F; Hou W; Fu J; Wang P; Zhao H; Sun J; Yang K; Zhou J; Li X
Ann Hematol; 2017 Dec; 96(12):2005-2013. PubMed ID: 28940056
[TBL] [Abstract][Full Text] [Related]
6. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
7. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
8. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.
Hou W; Zhang Y; Jin B; Cao W; Lu M; Yan L; Yang H; Tian X; Hou J; Fu J; Zhao H; Li H; Zhou J
Blood Cells Mol Dis; 2019 Nov; 79():102351. PubMed ID: 31400712
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
11. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
Chen X; Fan S; Zhao Y; Zhou J
Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
[TBL] [Abstract][Full Text] [Related]
12. [Effect of triple-induction regimen including all-trans retinoic acid, arsenic trioxide plus anthracyclines for adults with non-high-risk acute promyelocytic leukemia].
Ma RJ; Yuan XL; Jiang L; Yang SW; Yang J; Wang Z; Zhang P; Zhang L; Shang BJ; Cheng LN; Zhang Y; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2387-2391. PubMed ID: 34404132
[No Abstract] [Full Text] [Related]
13. Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
Zhao H; Zhao Y; Zhang Y; Hou J; Yang H; Cao F; Yang Y; Hou W; Sun J; Jin B; Fu J; Li H; Wang P; Ge F; Zhou J
Ann Hematol; 2018 Mar; 97(3):409-416. PubMed ID: 29289982
[TBL] [Abstract][Full Text] [Related]
14. Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.
Wen J; Xu F; Zhou Q; Shi L; Liu Y; Yue J; Zhang Y; Liang X
BMC Cancer; 2023 Jan; 23(1):27. PubMed ID: 36611025
[TBL] [Abstract][Full Text] [Related]
15. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
Singh C; Karunakaran P; Yanamandra U; Jindal N; Kumar SR; Saini N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Kumar N; Naseem S; Ahluwalia J; Varma N; Varma S; Malhotra P
Leuk Res; 2023 Nov; 134():107392. PubMed ID: 37774447
[TBL] [Abstract][Full Text] [Related]
17. Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
Freyer CW; Peterson CE; Man Y; Przespolewski A; Baron J; Luger SM
Leuk Lymphoma; 2021 Mar; 62(3):696-702. PubMed ID: 33106056
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
19. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.
Zhang L; Zhu X; Zou Y; Chen Y; Chen X
Int J Hematol; 2011 Feb; 93(2):199-205. PubMed ID: 21287409
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
